This is an aggregated industry headline. Read the full story at FiercePharma →
Amgen rides Repatha renaissance as cardio wins keep cholesterol med's momentum rolling
As Amgen's flagship PCSK9 cholesterol drug Repatha enjoys a bit of a renaissance on the back of impressive cardiovascular risk reduction data last year, the company is confident it can keep that momentum running well past the end of the decade.
By FiercePharma
· Aug 5, 2026
· via FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFierceBiotech ↗
Contract research organization Icon announced a multi-year collaboration with Anthropic this week to bring Cla…
The WeekBriefing
A new analysis challenged a controversial federal-law provision that exempts certain orphan drugs from Medicar…
The WeekSTAT News ↗
The Senate investigation includes RFK Jr. as well as the heads of Reynolds American and kratom company Botanic…